The blood-brain barrier is an essential, highly selective vascular structure that tightly regulates the passage of molecules between the circulating blood and the central nervous system. By restricting the entry of harmful substances while allowing essential nutrients to pass, the BBB preserves the delicate cerebral milieu necessary for proper neural function. Intriguingly, the BBB endothelial cells contain a remarkably high density of mitochondria compared to endothelial cells elsewhere in the body, indicating a substantial energy demand intrinsic to their barrier function. Prior to this study, while mitochondrial dysfunction had been implicated in various neurodevelopmental and neurodegenerative disorders, its direct role in BBB integrity remained largely unexplored, especially in the complex pathological landscape of 22qDS.

The 22q11.2 deletion syndrome is a multifaceted genetic disorder resulting from the deletion of a small but critical region on chromosome 22 that encompasses approximately 30 to 50 genes, including six essential mitochondrial genes. Clinically, 22qDS manifests as a spectrum of phenotypes, ranging from cardiac anomalies to immune deficiencies, but what has increasingly captured the scientific community’s attention is the syndrome’s profound impact on brain development and function. Individuals with 22qDS face a 25-fold increased lifetime risk of developing psychosis, and schizophrenia diagnoses are prevalent in roughly 25% of affected patients. This confluence of genetic vulnerability and psychiatric pathology renders 22qDS an invaluable model for understanding neuropsychiatric diseases.

Within this intricate backdrop, researchers employed a multi-pronged experimental framework, combining human induced pluripotent stem cell (iPSC)-derived brain microvascular endothelial cells from individuals with 22qDS and corresponding BBB endothelial cells harvested from a validated preclinical mouse model bearing the same chromosomal deletion. This paired approach allowed the team to interrogate mitochondrial performance, BBB permeability, and the potential for pharmacologic remediation with remarkable precision. Their experiments unequivocally demonstrated that mitochondrial energy production was compromised in 22qDS models, translating to a “leaky” or dysfunctional BBB that likely facilitates aberrant molecular and cellular communication between the brain and systemic circulation.

One of the most compelling facets of the study was the identification of bezafibrate, an established lipid-lowering agent and a known activator of mitochondrial biogenesis and turnover, as a therapeutic candidate capable of rescuing BBB integrity. When administered to 22qDS mouse models and applied to human iPSC-derived endothelial cells, bezafibrate enhanced mitochondrial respiration, restored barrier tightness, and normalized the expression of critical endothelial junctional proteins. These biochemical and cellular improvements corresponded with a striking reversal of social memory deficits in the animal model—a behavioral abnormality tightly linked to both BBB compromise and psychiatric symptomatology. This preclinical evidence not only substantiates the mitochondrial basis of BBB dysfunction in 22qDS but also highlights bezafibrate’s potential as a repurposed drug for mitigating neuropsychiatric symptoms.

The implications of these findings ripple far beyond this rare genetic syndrome. Given the mounting recognition that BBB disruption is a common denominator in many neuropsychiatric and neurodegenerative disorders, targeting mitochondrial function within brain endothelial cells may represent a transformative approach to disease modification. The collaborative research team, led by Drs. Jorge Iván Alvarez of Penn Vet and Stewart A. Anderson of CHOP, emphasized the significance of a “One Health” perspective—integrating veterinary, biomedical, and clinical expertise—to unravel the complexities of mitochondrial influence on neurovascular health.

Prior investigations had already hinted at BBB abnormalities in 22qDS, but this study delineates, with unprecedented clarity, a mechanistic chain linking mitochondrial energetics to barrier function and consequent behavioral outcomes. The revelation that enhancing mitochondrial biogenesis with bezafibrate can mitigate these defects points toward a previously underappreciated axis of therapeutic opportunity. Moreover, the use of FDA-approved drugs accelerates the timeline for clinical translation, underscoring a pragmatic path toward intervention that could alleviate the considerable neuropsychiatric burden borne by many individuals with 22qDS.

At the molecular level, the study detailed the restoration of tight junction proteins such as claudin-5 and occludin upon bezafibrate treatment, crucial components in the architecture of the BBB that prevent paracellular leakage. Enhanced mitochondrial function was evidenced by increased ATP production and improved oxidative phosphorylation metrics, indicating rejuvenated cellular bioenergetics. This mitochondrial revival was critical not only for maintaining the structural integrity of the endothelial monolayer but also for preserving the dynamic signaling necessary for BBB adaptability and response to physiological stress.

Behaviorally, the preclinical mouse model exhibited pronounced social memory impairments, mirroring cognitive and social deficits seen clinically in schizophrenia and other psychiatric disorders associated with 22qDS. The reversal of these behavioral phenotypes following mitochondrial enhancement is a compelling demonstration that targeting cellular metabolism within the vascular component of the brain can exert far-reaching neurofunctional benefits. This insight reframes some psychiatric symptoms as downstream consequences of vascular and metabolic dysregulation rather than purely neuronal dysfunction.

The research was supported by a constellation of funding sources, including the Uytengsu-Hamilton 22q11 Neuropsychiatry Research Program at Stanford’s Maternal and Child Health Research Institute, multiple NIH grants, the Howard Hughes Medical Institute, and private foundations. This broad financial backing reflects the high priority accorded to deciphering neuropsychiatric disease mechanisms and the translational potential of mitochondrial-targeted therapies.

CHOP’s leadership in pediatric neuropsychiatric research, boasting the world’s largest clinic dedicated to 22qDS, alongside Penn Vet’s distinctive expertise in veterinary biomedical research, particularly in mitochondrial biology and regenerative medicine, created a uniquely fertile environment for this discovery. Their combined efforts exemplify cross-disciplinary innovation, leveraging stem cell technologies, advanced imaging, behavioral paradigms, and pharmacology to tackle a formidable medical challenge.

Looking forward, clinical trials will be indispensable to determine the safety and efficacy of bezafibrate and related mitochondrial activators in patients with 22qDS and potentially other neuropsychiatric conditions marked by BBB dysfunction. Should these trials confirm the preclinical promise, it would mark a paradigm shift toward targeting vascular bioenergetics as a means to mitigate cognitive and psychiatric impairments. This study not only advances fundamental science but also fuels hope for transformative treatments that improve quality of life for patients grappling with these complex disorders.

Subject of Research: Animals
Article Title: Bezafibrate improves mitochondrial function, blood-brain barrier integrity and social deficits in models of 22q11.2 deletion syndrome
News Publication Date: 20-Aug-2025
Web References: https://doi.org/10.1126/scitranslmed.ads2116
References: Crockett et al, “Bezafibrate improves mitochondrial function, blood-brain barrier integrity, and social deficits in models of 22q11.2 deletion syndrome.” Sci Transl Med. Online August 20, 2025. DOI: 10.1126/scitranslmed.ads2116.
Image Credits: The Alvarez lab of the University of Pennsylvania School of Veterinary Medicine
Keywords: Genetic disorders, Pediatrics

Neurexin-1 is a gene that encodes a crucial presynaptic cell-adhesion protein, which plays an essential role in forming and maintaining synaptic structures within the brain. The presynaptic terminal is pivotal for neurotransmission, and thus any disturbances in the activity or composition of neurexin-1 can lead to significant synaptic dysfunction. Notably, studies of the 2p16.3 chromosomal region highlight that heterozygous deletions in NRXN1 can lead to disrupted splicing patterns, which in turn can severely compromise the connectivity within neuronal circuits.

One of the intriguing aspects of NRXN1 is its complex alternative splicing. This process generates a wide array of isoforms of the protein, each tailored for the diverse needs of distinct neuronal populations. While alternative splicing is a common theme throughout many genes, the patterns specific to NRXN1 are particularly critical in establishing and maintaining synaptic integrity. The variability in splicing and the resulting diversity in isoform expression are not merely academic concerns; they are fundamental to our understanding of how specific mutations can manifest in disorders of the brain.

In research leveraging human-induced pluripotent stem cells (iPSCs), scientists have begun to elucidate the cell-type-specific ramifications of mutations within NRXN1. Initial findings indicate that patient-specific alterations in splicing lead to divergent effects on synaptic function in different neuronal populations. For instance, glutamatergic neurons, which primarily use glutamate as a neurotransmitter, appeared to experience decreased synaptic activity when affected by certain NRXN1 mutations. Conversely, GABAergic neurons, responsible for inhibitory neurotransmission, exhibited a notable increase in synaptic activity as a result of the same genetic aberrations.

These preliminary observations underscore the necessity for a nuanced perspective on gene mutations within the context of neuropsychiatric disorders. The divergent activities in glutamatergic versus GABAergic neurons highlight how similar genetic perturbations can lead to opposing functional outcomes, which raises challenging questions about treatment strategies. This complexity demands a more personalized approach to precision medicine, whereby patients can be stratified based on the nature of their mutations—whether they act through loss-of-function (LOF) or gain-of-function (GOF) mechanisms.

Understanding these mechanisms is vital for developing targeted therapies that could effectively mitigate the effects of specific NRXN1 mutations. The research indicates that for NRXN1 deletions, a comprehensive approach aiming to restore the correct balance of isoform expression could lead to improved therapeutic outcomes. For instance, increasing the expression of wild-type isoforms while simultaneously abrogating the deleterious effects of mutant isoforms could yield promising strategies for restorative therapies.

Moreover, the ongoing analysis of how mutations within the NRXN1 gene interact with various cellular pathways provides new insights into potential therapeutic targets. It has become increasingly clear that the interplay between LOF and GOF mutations offers a unique landscape in which targeted interventions could orchestrate a return to functional homeostasis in affected neurons. As the field of neurogenetics continues to evolve, the implications of these findings could extend beyond NRXN1, suggesting broader applications to other genes implicated in neuropsychiatric disorders.

As researchers delve deeper into the nuances of how specific gene mutations shape neural circuitry, the principles of precision medicine increasingly take center stage. The complexity highlighted by the study of NRXN1 underlies the pressing need for customized treatment plans that account for individual genetic makeups. With the prevalence of neuropsychiatric disorders on the rise, such tailored approaches may ultimately enhance our ability to restore balance in neural communication and connectivity.

Furthermore, it is essential to recognize that the implications of this research extend far beyond the laboratory. Educating health care professionals and the broader public about the intricacies of genetic mutations like those affecting NRXN1 will be crucial in shaping future therapeutic paradigms. As more patients receive genetic testing and outpatient interventions, the potential for early interventions targeting specific mutations grows exponentially.

In conclusion, the implications of significant deletions in NRXN1 illustrate a complex interplay between genetics and neurobiology that is only beginning to be understood. The meticulous exploration of LOF and GOF mechanisms offers a rich tapestry of insights for therapeutic development, emphasizing the importance of personalized medicine in addressing diverse neuropsychiatric conditions. Ongoing research efforts will undoubtedly further unravel the complexities behind these mutations, ultimately driving innovative and effective treatment strategies tailored to the needs of individual patients.

As we move forward, the study of NRXN1 serves as both a beacon of hope and a testament to the intricate relationship between genetics and brain health. By embracing the complexities surrounding gene mutations and their connected pathways, we stand on the cusp of revolutionary advancements in our approach to neuropsychiatric disorders, potentially transforming the landscape of treatment in profound ways.

Subject of Research: The impact of NRXN1 mutations on neuropsychiatric disorders and the implications for precision medicine.

Article Title: Phenotypic complexities of rare heterozygous neurexin-1 deletions.

Article References:

Fernando, M.B., Fan, Y., Zhang, Y. et al. Phenotypic complexities of rare heterozygous neurexin-1 deletions.
Nature (2025). https://doi.org/10.1038/s41586-025-08864-9

Image Credits: AI Generated

DOI: 10.1038/s41586-025-08864-9

Keywords: NRXN1, neuropsychiatric disorders, precision medicine, gene mutations, synaptic function, alternative splicing, glutamatergic neurons, GABAergic neurons, loss-of-function, gain-of-function, personalized therapy.